Discover Insmed's innovative therapies targeting rare diseases, with approvals like Brinsupri boosting potential.

Insmed gains FDA approval for Brinsupri in bronchiectasis, while analysts see multi-billion sales potential from its expanding pipeline through 2035 ...

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

Insmed (INSM) saw a significant price move of 87% over the past quarter, driven by pivotal product developments and regulatory milestones. The FDA's approval of BRINSUPRI as the first oral treatment ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

JPMorgan raised the firm’s price target on Insmed (INSM) to $135 from $111 and keeps an Overweight rating on the shares. The firm sees Brinsupri as a $7B product by 2033 in its lead indication alone ...

The FDA has approved Insmed’s Brinsupri™ (brensocatib 10 mg and 25 mg tablets) as the first drug authorized to treat ...

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...

Insmed has won U.S. Food and Drug Administration approval of Brinsupri as the first and only treatment for the chronic lung disease non-cystic fibrosis bronchiectasis. Insmed on Tuesday said the FDA ...